Safety and Efficacy of 188-Rhenium-Labeled Antibody to Melanin in Patients with Metastatic Melanoma

Figure 1

Imaging of patients with ¹⁸⁸Re-6D2 mAb. (a) Whole-body scintigraphic image of a patient from Phase Ia showing absence of ¹⁸⁸Re-6D2 uptake in normal melanized tissues: from left to right—0.4, 3, 5, and 20 hr images; (b) patient from Phase Ia study with mediastinal and lung metastases: top panel—¹⁸FDG PET/CT 10 days before the study, lower panels—SPECT/CT of ¹⁸⁸Re-6D2 mAb at 2, 8, and 24 hrs after injection, respectively; (c) patient from Phase Ia study with large pelvic mass: from left to right—¹⁸FDG PET/CT 10 days before the study, SPECT/CT of ¹⁸⁸Re-6D2 mAb 8 hrs after injection.